AGEN1777
anti-TIGIT bispecific
AGEN1777 is a first-in-class TIGIT bispecific which targets a major inhibitory receptor expressed on T and NK cells to improve anti-tumor activity.
TIGIT is a negative regulator of innate and adaptive immune responses.
Phase 1 target 2021.